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Abstract 
Small molecules are often found to exhibit extraordinarily diverse biological activities. 
Metformin is one of them. It is widely used as anti-diabetic drug for type-two diabetes. In 
addition to that, metformin hydrochloride shows anti-tumour activities and increases the survival 
rate of patients suffering from certain types of cancer namely colorectal, breast, pancreas and 
prostate cancer. However, theoretical studies of structure and dynamics of metformin have not 
yet been fully explored. In this work, we investigate the characteristic structural and dynamical 
features of three mono-protonated forms of metformin hydrochloride with the help of 
experiments, quantum chemical calculations and atomistic molecular dynamics simulations. We 
validate our force field by comparing simulation results to that of the experimental findings. 
Nevertheless, we discover that the non-planar tautomeric form is the most stable. Metformin 
forms strong hydrogen bonds with surrounding water molecules and its solvation dynamics show 
unique features. Because of an extended positive charge distribution, metformin possesses 
features of being a permanent cationic partner toward several targets. We study its interaction 
and binding ability with DNA using UV spectroscopy, circular dichroism, fluorimetry and 
metadynamics simulation. We find a non-intercalating mode of interaction. Metformin feasibly 
forms a minor/major groove-bound state within a few tens of nanoseconds, preferably with AT 
rich domains. A significant decrease in the free-energy of binding is observed when it binds to a 
minor groove of DNA. 
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 INTRODUCTION 
In medical applications, small drug molecules display amazing conspicuous remedial actions, 
often life-saving. In most cases, the reasons for these striking biological activities are not 
understood at a molecular level. Sometimes the cause of the remedial action lies at the receptors, 
sometimes at proteins and sometimes with drug-DNA interactions
1
. A detailed molecular level 
understanding of the action can pave the way for development of better drugs.  Sometimes the 
drug molecules show unique and unusual characteristics. Thus, the physical chemistry of these 
drugs can be of great interest as a novel physical chemistry problem. 
The small molecule Metformin (N,N-dimethylbiguanidine), in its protonated form as 
Metformin Hydrochloride,  is used worldwide as a front line anti-diabetic drug for type-two 
diabetes.
2-3
 Hyperinsulinemia and insulin resistance by the cells are the primary reasons for this 
disease. For diabetic patients, metformin hydrochloride (hereafter referred to as MET) works by 
improving the insulin sensitivity of the cells. As a result, the cell receptors can recognize insulin 
molecules and insulin gets diluted in the blood stream. Apart from this well-studied part, MET 
also plays quite diverse, lesser known, role. Recent studies report a possible connection between 
increased risk of certain types of cancers and type-two diabetes
4
. MET activates adenosine 
monophosphate activated protein kinase (AMPK) that results in a decreased rate of tumor 
growth.
5
 It also targets certain types of cancer cells and oncogenes both in vivo and in vitro.
6-8
 
Clinical oncologists often use MET as a potential anti-tumor agent simultaneously with 
chemotherapy on cancer patients.
9-11
 
MET is available as an over-the-counter drug in an affordable rate than other medicines of 
similar category. The dose may vary from 50mg to 2000mg per day
12
. Due to the high doses, in 
some parts of the world, metformin is found in water bodies and sewages which causes water 
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pollution and hampers marine bio-diversity
13
. Whether there are a number of facts and 
information available in terms of medical knowledge and mere speculations, a detailed 
theoretical investigation at the molecular level is clearly lacking. This should be the first step 
towards understanding the mechanism and drug action of not only MET but also many other 
biologically important small molecules, which is, as of now, difficult and only partially 
understood.
14-15
  
There exist thermodynamic and kinetic studies of DNA intercalation of several small 
molecules like daunomycin, cis-platin, proflavine etc.
16-20
 However, relatively lesser number of 
theoretical studies are present.
21-25
 The general pathway of drug intercalation can be thought of 
as a combination of diffusion, outside groove binding and finally intercalation. However there 
are other kinetic models as well. Some molecules, for example, Hoechst, DAPI, methyl red etc. 
are found not to intercalate at all. These form a groove bound state with DNA but may possess 
anti-tumor and antimicrobial properties.
26
 The interaction of small molecules with DNA is also 
associated with DNA damage.
27
 
Although studies on the binding/ intercalation/ interaction of small molecules to protein/DNA 
has remained in the frontline for many decades, especially in disciplines like molecular biology 
and biophysical chemistry, our understanding of such processes has been slow to develop, 
because of the immense complexity of the systems involved. The delocalized positive charge on 
metformin hydrochloride makes it a potential ligand for DNA binding. Although there are no 
solved crystallographic or microscopy data for DNA-Metformin complex, the pre-intercalative 
outside bound state draws avid attention. However, the crystal structure of metastable metformin 
which is important for any medicine that are distributed in the solid phase, is recently solved
28
. 
Experimental studies of its interaction with biomolecules are also emerging.
18, 29
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In this paper, for the first time, we present a detailed molecular level study of metformin 
hydrochloride and its interaction with DNA with the help of computer simulations, quantum 
chemical calculations and spectroscopy. In the present work, we first characterize the molecule 
MET by investigating some of its structural and dynamical properties in aqueous solution. We 
perform quantum chemical calculations and molecular dynamics simulations to describe the 
molecule along with its different protonation states. We find that the non-planar protonated form 
exhibits maximum stability. We use an AMBER based force-field description. The validity of 
thus obtained force field is checked with respect to experiments. We then perform free energy 
calculations to understand the pathway of DNA binding with the help of metadynamics based 
sampling techniques. 
 COMPUTATIONAL METHODS 
Quantum chemical calculations and force field. In aqueous solution and at physiological pH 
(~6.9-7.4), metformin remains in the mono-protonated state. There are two possible protonation 
sites (Figure 1b, 1c) and these two protonated forms can tautomerise to produce another form 
(Figure 1d). We arrive at the energy minimized structure for each molecule using density 
functional theory (DFT) calculation with B3LYP functional and 6-31G + (d, p) basis set. Water 
is considered as an implicit solvent to provide a dielectric continuum during the optimisation. 
The optimized structures are further optimized using second order Møller-Plesset (MP2) 
perturbation theory method with the combination of augmented correlation consistent double 
zeta (aug-cc-pVDZ) standard basis set in order to obtain the final geometry and relative energies. 
We use this information to build the topology for simulation. In order to obtain the UV-VIS 
spectra, time dependent density functional theory (TDDFT) is applied for 10 states. All quantum 
calculations are performed with Gaussian 09 package
30
.  
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System and simulation details. Based on the relative stability and presumable co-existence, 
we choose three structures for molecular dynamics simulations (MET1, MET2 and MET3) as 
described in Figure 1. The geometry information (bonds, angles and dihedrals) are obtained 
from the respective optimised structures. Charges are calculated by RESP method that considers 
equivalence of atomic positions
31
. Other force field parameters (for example, LJ parameters, 
force constants etc.) are obtained by comparing the atom types with generalized amber force 
field (GAFF)
32
 atom types and using antechamber package (force field and topology parameters 
are provided in Supporting Information). 
We perform atomistic molecular dynamics simulations using GROMACS
33
 (v 5.0.7). Three 
different systems are set up for three different molecules as mentioned above. For each system, a 
single metformin molecule is solvated in ~500 TIP3P water molecules inside a cubic cell to 
comply with the experimentally studied concentration. In order to neutralize the charges chloride 
ions are added. We study the system size dependence of diffusion in 3 more systems that are 
generated in the same concentration (with 1440, 2880 and 4320 water molecules). 
For free energy studies of DNA binding, we prepare two model B-DNA dodecamer using 
nucleic acid builder (NAB) module implemented in AMBER
34
. The sequences are 
d(GCGCTCGAGCGC)2 and d(ATATCTAGATAT)2. As there are no solved crystal structures or 
microscopy image of DNA-MET complex, we prepare complex with the help of Maestro code in 
Schrӧdinger package.35 Here we show the free energy calculation for only DNA-MET3 complex 
as it is the most stable one in the physiological conditions. The DNA molecules are described 
using Amber99sb-ildn force field
36
 which is compatible with small molecules described by 
GAFF
32
. The prepared DNA-MET3 complex is solvated into 21010 TIP3P water molecules. 
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Charge neutralization is achieved by adding 22 Na
+
 and 1 Cl
-
 ions. Periodic boundary conditions 
are imposed in three dimensions.  
 The systems (described above) are energy minimized using steepest descent method 
followed by conjugate gradient method. Simulated annealing is applied starting from 300K to 
330K and again reducing the temperature slowly to 300K. We equilibrated the systems first by 
restraining the positions of the solutes for 2ns and then by removing the restrain for another 5ns 
in NPT ensemble (300K, 1bar). Then the equilibrated systems are subjected to 5ns NVT (300 K) 
simulations in order to achieve the desired equilibrium states. For MET-Water systems the final 
production runs are carried out for 10 ns. Metadynamics simulation details and description of 
order parameters are elaborated in Sec. G under ‘results and discussions’.  
 Modified Berendsen thermostat and Parrinello-Rahman barostat are used to keep the 
average temperature and pressure constant respectively. The equations of motion are integrated 
using a MD time-step of 2 fs. The cut-off radius for neighbor searching and non-bonded 
interactions is taken to be 10 Ȧ. All bonds are constrained using LINCS algorithm. PME is used 
for calculation of electrostatic interactions with FFT grid spacing of 1.6 Ȧ. 
 RESULTS AND DISCUSSION 
(A) Structure and Protonation States 
Metformin has more than one protonation sites that are crucial for determining its structure in the 
aqueous medium. pK1 and pK2 of neutral metformin molecule in gas phase is measured to be 3.1 
and 13.8 respectively. Metformin is neutral when the pH is greater than pK2. When the pH is in 
between pK1 and pK2 (that is, physiological pH), metformin captures a single proton and remains 
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positively charged. In conditions pH<pK1, it goes to a di-protonated form. We study only the 
mono-protonated forms as these are biologically important. 
 
Figure 1. Various protonation states of metformin, their geometry and relative stability as 
obtained from MP2 level optimization and energy minimization in water as an implicit 
solvent. Phi (∅) denotes the angle between the planes of two guanidine groups. It is seen 
that planar forms (b) and (c) are of comparable stability but the tautomeric non-planar 
protonated form (d) is of the lowest energy. The stability of the non-planar form is because 
of the release of the steric strain with a hydrogen and methyl groups as indicated in the 
figure in red. 
 
 The neutral form in water is not planar. We choose the energy of the neutral form along 
with an isolated proton in dielectric continuum as the reference frame for energy. With respect to 
this, MET1, MET2 and MET3 possess stabilization energies of ~185.6 kcal/mol, ~187.3 
kcal/mol and ~193.3 kcal/mol (Figure 1). We have performed another set of optimization and 
energy calculation by using the same level of theory but in the presence of explicit water 
molecules in the first hydration shell. As before, we set the reference to the energy of the neutral 
form and an isolated proton. With respect to this reference, MET1, MET2 and MET3 possess 
relative stabilization energy of ~150.7 kcal/mol, ~155.2 kcal/mol and ~157.7 kcal/mol 
respectively. That is, all the protonated forms are substantially more stable compared to the 
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neutral one; as shown by our quantum calculations. Addition of a proton induces planarity to the 
system. But, surprisingly the most stable form, that is the tautomeric form MET3, is non-planar. 
We can rationalize this extra stability of MET3 in the following fashion. We note that the 
conjugation is preserved in the non-planar form. We note that the two guanidine subunits retain 
their charge delocalization. In MET1 and MET2 there is one stabilizing hydrogen bond 
interaction (shown by green dashed lines in Figure 1) and another destabilizing steric hindrance 
between one methyl group and an hydrogen atom in the middle (shown by red color in Figure 
1). However, MET3, because of its puckered structure, loses the stabilization through hydrogen 
bond but at the same time, overcomes the steric strain. We speculate the steric effect 
predominates and makes MET3 the most stable mono-protonated form. 
(B) Choice of Protonation States and Validation of Force-field 
In order to identify the predominant protonated form in nature and validate the force field 
which we use in subsequent atomistic molecular dynamics simulations, we carry out experiments 
to determine a few basic properties like diffusion coefficient using diffusion ordered NMR 
spectroscopy (DOSY). The spectral characterization is also done with respect to UV-VIS, IR and 
NMR to get structural information. Experimental results are compared to those of theoretical 
findings.  
Crystallization and purity of the drug. We isolate crystals of pure metformin hydrochloride 
from Glycomet IP 500 mg, a commercially available prescription drug containing metformin, 
manufactured by US Vitamins Limited. Two 500mg tablets are ground thoroughly using mortar 
– pestle and stirred in water at 70° C for seventy two (72) hours. The resultant suspension is 
filtered and the clear filtrate thus obtained is cooled slowly over a couple of days to yield needle 
shaped white crystals of pure metformin. We characterize the purity of the sample using 
1
H 
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NMR. A few milligrams of the crystal is dissolved in D2O (99.9% D, Sigma Aldrich) and NMR 
data is recorded in a Bruker 400 MHz machine. Bruker Top Spin processing software is used for 
the data analysis. The observed NMR spectrum shows only one compound peak at 3.03 δ ppm 
(Supporting Figure S1) corresponding to the methyl protons of metformin structure, thus 
confirming the purity of the crystals obtained (indexed to The Human Metabolome Database 
entry HMDB0001921)
37
. The crystals are found to melt between 232 – 234°C. Melting of 
different polymorphs of metformin hydrochloride has been reported in literature to occur within 
the temperature range 224° C to 232° C.
38-39
 
UV-VIS spectroscopy. We perform UV Visible absorption experiments using a 50 µM 
solution of Metformin in water in 10 mm path length quartz cuvette, on a Perkin Elmer Lambda 
750 spectrophotometer. The wavelength window used is 200 – 800 nm. The UV-Vis absorption 
spectrum of Metformin in water shows a strong absorption centered around 230 nm which arises 
due to nπ* transition characteristic of the imine moiety40. Variation of concentration from 15 
µM to 150 µM shows no significant changes in the absorption spectrum, apart from the expected 
linear increase in absorption of the 230 nm peak (Supporting Figure S2). A resultant Lambert – 
Beer analysis is used to estimate the molar extinction coefficient as 10240 (±230) M
-1
cm
-1
. 
TDDFT calculations provide the probable UV - visible spectra for different protonated species 
(Figure 2).  
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Figure 2. Characterization of the protonate state of metformin is demonstrated by 
combining UV – visible absorption spectrum of metformin obtained from experiment (A: 
orange circles represent the data points, the orange trace represent the Gaussian fit) and 
by TDDFT calculations for three different protonated species (B). In the experimental 
spectrum the absorption peak is at ~230 nm. The theoretically calculated spectrum for 
MET3 (~235 nm) is closest to the experimentally observed absorption spectrum of 
metformin hydrochloride in solution which indicates the predominance of the form MET3 
in the experimental sample. 
 
Out of the three probable forms, the one that is found to be closest to experimental data 
corresponds to the tautomeric form MET3, which, we conclude, is the predominant form in 
aqueous solution. The theoretically calculated absorbance peak for MET3 cantered at 235 nm is 
in good agreement with the experimentally observed absorption spectrum at 230 nm. So we draw 
most of our conclusions by studying this tautomeric form alone. This form shall be used later 
when we study its interaction with DNA.  
 
Diffusion Coefficient Measurements. 
1
H Diffusion Ordered Spectroscopy (DOSY) is 
performed on a Bruker 400 MHz spectrometer using the NMR sample prepared as discussed 
earlier. Bruker TopSpin processing software is used for the data analysis. The diffusion 
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coefficient corresponding to the metformin molecule in D2O is found to be 0.98 X 10
-5
 cm
2
/s 
from DOSY spectrum. This value of D is used to estimate the hydrodynamic radius (rH) of 
metformin using the Stokes-Einstein equation shown below. 
 
6
B
H
k T
D
r
  (1) 
Here viscosity coefficient (η) is 1.2503 X 10-3 Nm-2s for D2O
41
 and the calculated rH is 1.76 Å. 
The diffusion coefficient obtained from DOSY is 0.98 X 10
-5
 cm
2
/s, which is again closer to the 
calculated diffusion coefficient in water at similar conditions from MD simulations.  
In our computer simulation studies, we use mean squared displacement (MSD) to find 
diffusion constant from the slope of MSD vs time graph with the help of the following Einstein 
equation. 
 2( ) 6r t Dt    (2) 
The deviation from experiment is small which provides strong support in favor of the force 
field of metformin (Figure 3 and Table 1). As the calculation of diffusion constant is dependent 
on the system size we perform four simulations with different system size and report the values 
for the largest system size (that is 9 MET in 4320 water molecules) in Table 1. The dependence 
of diffusion constant on system sizes is discussed in the Supporting Information (Table S1) 
section. The trend in the diffusion coefficients can be explained in terms of the average hydrogen 
bond lifetime of MET with water (Table 3). The average H-bond lifetime for MET1, MET2 and 
MET3 are 5.8ps, 5.1ps and 4.5ps respectively. That indicates a lesser resistance experienced by 
MET3 which eventually increases its diffusion in liquid water.  
However, the diffusion coefficient values do not demonstrate the abundance of MET3 in the 
experimental sample. The values obtained from simulations of different protonated forms are 
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fairly close to each other. We note that the solvent used in DOSY experiments is heavy water 
(η~1.25 mPa.s) as opposed to that of the neat water (η~1 mPa.s) used in simulations. As the 
coefficient of viscosity of D2O is 25% higher than H2O, it only scales the diffusion coefficient by 
~25% as Eq. (1) is quantitatively valid in this range. Hence, the calculated diffusion constants 
can be compared with the experiments. 
 
 
Figure 3. DOSY spectrum of metformin hydrochloride in D2O showing the diffusion 
constant corresponding to metformin molecule and D2O (left); MD simulation data used 
for estimation of diffusion coefficient of metformin in its various protonated forms using 
mean squared displacement versus time plot (right) - MET1 (black), MET2 (red) and 
MET3 (green).  
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Table 1. Diffusion coefficient of metformin as calculated from DOSY experiment and 
separately from classical molecular dynamics simulation. The results are noted down here 
for the largest simulation box (that is with 4320 water and 9 metformin molecules). 
Dependence on system size is given in the supporting information section (Table S1). 
 D (experimental) cm
2
/s D (simulation, in H2O) cm
2
/s 
MET1 50.98 10 (in D2O) 
[that is, 
51.23 10 (in H2O) 
by viscosity scaling 
according to Eq.1 ] 
51.13( 0.35) 10   
MET2 51.25( 0.45) 10   
MET3 
51.47( 0.53) 10   
 
Infra-red Spectroscopy. We use IR spectroscopy to identify the vibrational modes of 
different bonds in metformin. IR experiments are carried out in ATR mode using pure crystals of 
the drug on a Perkin Elmer Frontier instrument within the wavenumber window of 400 – 4000 
cm
-1
. The IR spectrum of the compound is shown in Figure 4. The primary bands seen in IR are 
indexed to vibrational modes expected in the metformin molecule (Table 2) using standard data 
available in literature
42
. 
We next compare the experimentally obtained spectrum with that from quantum chemical 
calculations. Table 2 contains the detailed description of the absorption bands. 
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Figure 4. Characterization of protonation states of metformin with the help of Infrared 
spectrum (a) experimentally and (b)-(d) with the help of quantum calculations on three 
different protonation states in implicit water solvent. It is clear that the tautomeric form 
resembles more with the experimental spectra. This again proves the dominance of the 
tautomeric form in the experimental sample.   
 
 The broad absorption band at ~1400-1600 cm
-1
 is the characteristic absorption band for 
N-H bending mode of imine group. This feature is also present in the theoretically calculated 
spectrums. Additionally there is considerable absorption ~3200 cm
-1
 for MET1 and MET2 
forms, as obtained from theory. This band is absent in MET3 as well as in the experimental 
spectra. This again proves the dominance of MET3 form among other protonated forms. In the 
later section where we discuss the interaction with DNA, only MET3 is considered. 
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Table 2. Vibrational modes identified from IR Spectrum of metformin 
Wave number / cm
-1
 
 
Vibrational Mode 
 
3370 C=N-H (Imine) 
3290, 3149 N-H stretching / symmetric 
3901 C-H stretching / asymmetric 
1622 >C=N stretching 
1553 N-H bending vibration / Imine 
1472, 1447, 1416 
Asymmetric C-H deformation in 
N(CH3)2 
1275, 1246, 1217, 1166 NH2 rocking / twisting 
1081, 1062, 1040 CH3 rocking vibration 
937 Symmetric C-C=N stretch 
800, 736, 695, 655 N-H out of plane bending 
 
Melting Studies from Simulation. Melting studies are yet another way to check the 
robustness of the force field. The crystal structure of a polymorph of the tautomeric form of 
metformin is solved by Patrick et al.
28
 This is again the tautomeric form that we claim is the 
most abundant. We use the crystal structure to build a monoclinic simulation box (4.077nm X 
7.154nm X 3.717nm and α=90°=γ, β=114°) of 450 MET3 molecules (that is 450 metformin-H(+) 
and 450 Cl
-
). By the use of simulated annealing technique, we rise the temperature from 0K to 
1000K in steps of 20K and equilibrated the system (NPT) until it attains a stable value of density. 
Each configuration is further equilibrated for 100 ps in NVE ensemble. Hence, there are fifty 
trajectories that correspond to fifty different temperatures.  
 16 
 Two kinds of analyses are performed to identify the melting point of the crystal. The first 
one is to investigate the nature of the radial distribution function (RDF) of center of mass of 
MET. The position and the height of first peak drastically changes near melting point (Figure 5a 
and 5b). Another way is to monitor the potential energy (Coulomb and LJ) per molecule with 
temperature. It also shows a break in the slope near the melting point (Figure 5c). In Figure 5d, 
we show the variation in density with temperature with a similar break near 568K. All three 
studies reveal the melting point ~568K whereas the experimentally measured melting point is 
~505K. Our force field description overestimates the melting point by ~12% which is usually 
regarded as a good agreement in the existing literature on force-filed development. The 
discrepancy may be partly because of the way the force field is developed. It is not suitable to 
describe the molecule in its solid state. Despite it predicts the melting point only 12% higher. 
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Figure 5. Broad agreement of the melting point temperature between simulation results 
and experimental studies of MET crystal as reported by Patrick et al
28
. (a) Exemplary plots 
of radial distribution function (RDF) of centre of mass of metformin molecules in four 
different temperatures. The nature of the peaks and their positions dramatically changes 
when the crystal melts. (b) First peak position versus temperature plot. This shows a 
discrete jump around 568K. This can be considered as the melting temperature. (c) 
Potential energy per molecule against temperature also shows a break in the slope near 
568K that also suggests melting. (d) Density against temperature plot shows a break in the 
slope near 568K. 
Preservation of the Geometry of Metformin. In order to check the ability to retain the 
conformation we perform ~100ns well-tempered metadynamics simulation on MET-TIP3P 
(1:500 molecules) water system. We consider two torsion angles as order parameters with 
Gaussian hill height of 0.5 kJ/mol and width of 0.05 radians (for dihedrals). It is similar to the 
Ramachandran’s plot in case of peptides. These two dihedral angles are defined in Figure 6. It is 
clear that MET1 and MET2 have the lowest free energy when they are planar. On the other hand 
some amount of puckering is associated with the free energy minima of MET3. The second patch 
in the free energy surface of MET3 arises because of another similar conformation when ϕ1 
rotates by 180°. However up to our several ns during unbiased MD simulation, because of the 
high energy barrier of escape (greater than 40 kJ/mol), the molecules are able to retain its 
conformation which corresponds to the deepest free energy minima.    
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Figure 6. Free energy (in kJ/mol unit) contours with respect to two dihedral angles (ø1 and 
ø2) of the three different mono-protonated forms of metformin hydrochloride. Because of 
the deep minima in free energy all three of them preserve the planar/non-planar 
conformation to a great extent under our force field description. In the timescale of 
performed MD simulations they are observed to evolve only in the deepest minima. 
(C) Energy Barrier of Proton Transfer 
 
Figure 7. Schematic representation of proton transfer reaction from one to another planar 
mono protonated form. The barrier crossing energy is low (~4-6 kCal/mol) which allows a 
possible co-existence of these two species in the solution.  
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 In order to find out the possibility of co-existence among the various protonated forms we 
calculate the energy barrier of proton transfer between MET1 and MET2. The transition state 
(TS) is optimized by using the same level of theory (optimized to Berny TS) as the stable 
structures and traced back to the reactant/products by the use of internal reaction coordinate 
(IRC) scan. We find that the energy barrier for MET1  MET2 is ~4.4 kcal/mol and for that of 
MET2  MET1 is ~6.1 kcal/mol (Figure 7). The energy barrier can be crossed in room 
temperature and allows us to speculate a possible co-existence between the two forms of 
metformin hydrochloride in the aqueous solution.  
(D) Water Molecules around Metformin 
Radial distribution function. The partial pair correlation functions [gαβ(r)], where α stands for 
either N or H of metformin and β stands for the oxygen atom of water molecules, are calculated 
in order to realise the local structure of water molecules around metformin hydrochloride. gαβ(r) 
is calculated from the classical MD trajectories. We match this result to the ab-initio calculations. 
We put explicit water molecules around metformin (Figure 8) and optimized the whole system 
by using MP2/aug-cc-pVDZ. We find that the water molecules are stabilized at a distance of 
~3Ȧ from the N-atoms and ~2Ȧ from the H atoms. This provides some rationalisation in the 
calculated g(r) from MD simulations (Figure 9). Also that the tautomeric form is non-planar and 
the most stable in explicit water solvent.  
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Figure 8. Representation of the optimised structures of various protonated forms of 
metformin hydrochloride in explicit water molecules (five) as a solvent. The water 
molecules are stabilised at ~2-3 Ȧ. We observe that the tautomeric form is the most stable 
one here as well with a non-planar geometry.  
 
Figure 9. Radial distribution functions between certain atoms of metformin and oxygen 
atoms of water. (a) Pair correlation function between nitrogen atoms of metformin and 
oxygen of water. This shows two peaks ~3Ȧ and 5Ȧ. (b) pair correlation function between 
acidic hydrogen atoms of metformin and oxygen of water. This shows two peaks ~2Ȧ and 
3.5Ȧ. 
 
Hydrogen bond dynamics. Because of the presence of six nitrogenous hydrogen atoms there 
can be extensive hydrogen bonding between MET and water molecules. The hydrogen bond 
lifetime and strength are reflected in self-diffusion, orientational mobility and solvation (as 
discussed later). We employ a technique that was developed by Chandler et al. using of 
 21 
Heaviside step function (H or h) formalism
43
. We use the usual geometric criteria as the 
definition of hydrogen bond. h(t) adapts a value equal to ‘1’ if the bond is present and ‘0’ 
otherwise. On the other hand, H(t) is ‘1’ if the bond is present and ‘0’ for the rest of the 
trajectory if the bond breaks only once. We can define two types of time correlation functions 
using these definitions namely continuous hydrogen bond correlation, SHB(t) and intermittent 
hydrogen bond correlation, CHB(t) as defined in Eq (3). 
 
(0) ( ) (0) ( )
( ) ; ( )HB HB
h h t h H t
C t S t
h h
   (3) 
Surprisingly the three protonated forms of metformin hydrochloride show quite distinct 
hydrogen bond dynamics and lifetime (Figure 10 and Table 3). Moreover, the trend is 
completely opposite in CHB(t) and SHB(t). It happens because water molecules can come near 
MET and goes away in the next step. But it can again come back and this cycle goes on for a few 
ps. In that situation SHB(t) picks up ‘0’ forever but CHB(t) oscillates between ‘0’ and ‘1’. 
 
Figure 10. Hydrogen bond dynamics between metformin and water molecules. (a) 
Intermittent hydrogen bon correlation function. (b) Continuous hydrogen bond correlation 
function. 
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Table 3. Timescales of hydrogen bond dynamics for three protonated forms of metformin 
hydrochloride.  
Correlation 
function 
Molecule a1 τ1(ps) a2 τ2(ps) <τ>(ps) 
CHB(t) 
MET1 0.49 0.51 0.51 10.81 5.8 
MET2 0.41 0.33 0.59 8.40 5.1 
MET3 0.39 0.38 0.61 7.14 4.5 
SHB(t) 
MET1 0.85 0.01 0.15 0.16 0.032 
MET2 0.86 0.01 0.14 0.23 0.041 
MET3 0.88 0.01 0.12 0.42 0.059 
(E) Dynamical Features of Metformin in Aqueous Solution: Orientational 
Correlation 
We investigate the rotational dynamics of MET in the form of first and second rank rotational 
time correlation functions as defined below, 
 1 1 0 1ˆ ˆ( ) P ( . ) ; whereP ( )tC t x x    (4) 
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2 2 0 2 2
ˆ ˆ( ) P ( . ) ; whereP ( ) (3 1)tC t x x     (5) 
Here, P1 and P2 are respectively the first and second rank Legendre polynomials and t is the unit 
vector along N2—N4 axis (see Figure 6) of metformin. The rotational time constants are quite 
comparable for all three forms (Figure 11). These time constants are obtained by fitting the 
resultant curves with a multi exponential function and the average time constants are obtained by 
integrating the area under the curve with respect to time, as shown in Table 4. 
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Figure 11. First (left, a) and second rank (right, b) rotational time correlation function for 
three different protonated forms of metformin. The three protonated forms show slightly 
different rotational dynamics with distinct time constants noted down in Table 4.  
Table 1. Timescales of first and second rank orientational dynamics for three protonated 
forms of metformin hydrochloride. 
Correlation 
function 
Molecule a1 τ1(ps) a2 τ2(ps) <τ>(ps) 
C1(t) 
MET1 0.05 3.83 0.95 36.52 34.9 
MET2 --- --- 1.0 26.82 26.8 
MET3 --- --- 1.0 38.84 38.8 
C2(t) 
MET1 0.18 5.99 0.82 19.3 16.9 
MET2 --- --- 1.0 14.5 14.5 
MET3 0.03 0.21 0.97 20.4 19.8 
 
Because of the asymmetric charge distribution of MET there exists a considerable 
contribution form dielectric friction in addition to Stokes’ friction. This makes the dynamics non-
Markovian and results in multiple timescales.
44
 Hence we obtain a multi exponential fit. 
However, in some cases the time scales are fairly close to assume a single exponential behavior.  
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(F) Solvation Dynamics of Metformin Hydrochloride 
Solvation of small molecules is investigated in great details in several earlier studies.
45-47
 It 
gives a measure how rapidly the surrounding dipolar solvent can respond to the changed charge 
distribution of the solute.
44, 48-49
 Ideally it should be calculated from either non-equilibrium 
simulations or TDFSS experiments but that needs a proper identification of the excited states. 
However, under linear response approximation, time auto-correlation function of electrostatic 
interaction energy of metformin
(+)
 with water molecules and ion equivalent to the non-
equilibrium stokes shift response function measured by TDFSS experiments as described in Eq. 
(6).
44, 50-51
 We calculate the time correlation function from a 5ns MD trajectory (at 2 fs trajectory 
dumping rate). 
 
2
(0) ( )( ) ( )
( )
(0) ( ) (0)
E E tt
S t
E
  
  
 
 
 
 (6) 
Here, ( )E t  is the fluctuation in the interaction energy at time ‘t’. The resultant data is fitted 
to a tri-exponential function with an initial Gaussian component. The solvation of metformin 
hydrochloride is found to be ultrafast with an average time constant ranging from 130 to 160 fs 
with three distinctly different time constants (Table 5). One such exemplary plot is shown in 
Figure 12 for MET3. Faster solvation dictates the increased stability of MET in liquid water. 
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Table 2. Solvation timescales of three protonated forms of metformin hydrochloride in 
liquid water. Each of them shows ultrafast solvation with three different time scales. The 
fitting parameters are noted down in this table after fitting the resultant solvation energy 
time correlation function [Eq.(6)] to a tri-exponential function with an initial Gaussian 
decay [
2
2 2
1
( ) exp( / ) exp( / )
g g i i
i
S t a t a t 

    ].  
Molecule ag τg (fs) a2 τ2 (fs) a3 τ3 (fs) <τ> (fs) 
MET1 0.36 10 0.48 115 0.16 598 154.5 
MET2 0.38 10 0.47 96 0.15 547 131.0 
MET3 0.35 10 0.44 100 0.21 530 158.5 
 
 
Figure 12. (a) Total solvation energy relaxation for the tautomeric form of metformin 
hydrochloride (MET3) in water. (b) Layer wise decomposition of solvation energy 
relaxation that shows the role of second layer in the observed oscillations in total solvation 
energy relaxation. 
The solvation time correlation function is oscillatory in nature. We perform layer wise 
decomposition of the total solvation response to isolate the origin of these oscillations (Figure 
12).
51
 The Y-axis in Figure 12(b) is the relative contribution to the total solvation by each layer 
around metformin. There are negative-amplitude cross terms (not shown here) which neutralizes 
the large slow component arising from self-terms.  
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 We observe that the initial oscillations in the solvation energy time correlation function 
arise primarily due to the second layer that has the highest amplitude as well. Because of the 
strong electrostatic interactions and long lived hydrogen bond formation ability of metformin
(+)
 
with the water molecules in the first shell, the ones in the second shell is more mobile and 
contributes to the oscillations that arises due to librational motion. 
(G) Interaction and Binding with DNA 
Theoretical Investigations 
Because of the extended positive charge on the molecule, MET possesses a natural tendency to 
be attracted by DNA which is rich on negative charge on the phosphate backbone. In order to 
study the stability and pathway of formation of an outside groove bound state of MET3 we first 
prepare a docked structure with two model B-DNA dodecamer. The preferable docking position 
is observed to be the minor groove. We start our simulation by considering this as the initial 
configuration (Supplementary Figure S4).   
In the case of metadynamics
52
 simulation, 170 ns production run is found to be convergent. 
Two variables are used as order parameters to generate the free energy surface (see Figure 13). 
(i) The distance between the center of mass (COM) of MET3 and the COM of the four closest 
base pairs (C7, T8, A17 and D18) in the initial structure of GC rich DNA-MET complex. In case 
of the AT rich DNA, the distance between the COM of MET3 and COM of two closest base pair 
(D7 and D18) is chosen as the distance parameter. Let us call the closest base pairs the DNA 
reference groups in the initial structure; and (ii) the angle between a fixed vector, starting from 
the COMs of the reference groups and perpendicular to the DNA axis (that is in the body fixed 
frame description), and another vector joining the centre of mass of MET3 to the starting point of 
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the previous vector. Hence this angle, if in between 0 to π/2 radian, indicates a minor groove 
bound state at the then a value between π/2 to π indicates major groove bound state at the initial 
configuration. However, these ranges shall be reversed when looked into the next turn of DNA. 
Hence, we need to look at the trajectories carefully to locate the structure of the complex inside a 
given free energy well.  
The Gaussian hill height and width are taken to be 0.5 kJ/mol and 0.05 (in nm and radian units 
for distance and angle) respectively. A bias factor of 6.0 was assigned for well-tempered 
metadynamics
53
. We perform metadynamics simulations using PLUMED 2.0 package
54-55
 
patched with GROMACS 5.0.7
33
.  
 
Figure 13. Pictorial representation of the two chosen order parameters in order to generate 
the free energy surface of DNA-MET complex by the use of metadynamics simulation. The 
center of mass of four bases (in case of GC rich DNA, shown by green dot A) that are 
closest to the centre of mass of the drug (shown by yellow dot B) in the initial condition is 
chosen as a reference point from where the distance (d) and angle (𝛟) are measured. In the 
above figure, AC vector is fixed with respect to the body fixed axis of DNA, but AB vector 
can change in both magnitude and direction as the drug explores different parts of the 
phase space during simulation. 
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 The free energy contours that are developed from the metadynamics simulation shows 
free energy minima regions (blue and indigo patches in Figure 14) in both AT and GC rich DNA-
MET systems. In case of AT rich DNA there are several free energy wells in the free energy map 
(Figure 14 a). On careful examinations of the trajectories, we confirm that MET can bind to 
minor or major grooves and even with the phosphate backbone as well. On the other hand, there 
is lesser amount of stable regions in the free energy map of GC rich DNA. This suggests that 
MET can preferably bind to AT rich grooves/domains. The free energy cost to escape the deepest 
minima is obtained to be ~12-14 kJ/mol. However, this value is comparatively smaller than the 
binding free energies of other known groove binders (for example, Hoechst).
56-58 
 
Figure 14. Free energy contours of DNA-MET system with respect to two order parameters 
as described in Figure 13. The blue patches represent free energy minima. (a) In case if A-T 
rich DNA (A-T content ~80%) there are more blue patches which indicates that MET can 
be stabilized at multiple places on the surface of AT rich DNA. (b) In the case of G-C rich 
DNA (G-C content ~80%) the area consisting of blue patches is less. MET cannot bind at 
many position on the surface of the GC rich DNA. With both the model DNA it forms outer 
groove bound (major/minor) and backbone bound states as confirmed from the trajectory. 
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 Because of the low free energy of binding, MET can escape the free energy well (that is 
the minor groove bound state) in room temperature and explore other regions on the DNA 
surface. Few such instances are shown in Figure 15 with the help of snapshots at different time 
points.  
Let us start from an arbitrary time t=0 where MET first binds to the major groove of AT rich 
DNA. General considerations based on the relation between diffusion and entropy, such as 
Adam-Gibbs
59
 or Rosenfeld scaling
60
, indicate that the major groove bound state is entropically 
favourable because of greater translational and rotational degrees of freedom, although there are 
plenty of other factors like hydrogen bonding and arrangement of solvent molecules in the 
neighbourhood.
61
 But the minor groove bound state is the global minimum. One interesting 
feature that is observed in our simulations is the restricted diffusion onto the DNA surface 
(Figure 15). It at first goes to a transient backbone bound state from the major groove. Then it 
slides into the minor groove pocket. This kind of feature appears to be a general characteristic of 
such small molecules in aqueous DNA systems.   
 
Figure 15. Diffusion of metformin on the surface of AT rich DNA. This sequence of figures 
depict how MET undergoes surface diffusion from major groove bound state to the more 
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stable minor groove bound state via a transient backbone bound state. The above figures 
are snapshots from metadynamics trajectories visualized using VMD
62
. 
 We set up another MD simulation (50 ns trajectory) without any bias potential with a B-
DNA dodecamer and 10 MET3 molecules. This allows us to observe the inherent tendency of 
selective groove binding. We start with a random configuration where all MET3 molecules are 
randomly placed away from the DNA. In Figure 16  we show the time evolution of the system. 
It is clear from the analysis of the trajectory that MET forms both major and minor groove bound 
state. But at the long time most of the molecules tend to form a minor groove bound state like an 
extended chain that has significantly large residence time (~10-30 ns). The residence time of 
MET in the minor groove is high. The drug molecules form an outside bound state within few 
tens of ns which is also seen for other drug molecules like proflavin.
23
 They become stable due to 
several strong hydrogen bond formations with the DNA base pairs that contribute to a higher 
Boltzman factor weightage. These results are consistent with the metadynamics results discussed 
above.  
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Figure 16. Time evolution of DNA-MET3 system where 10 MET and one GC-rich B-DNA 
is present. From the randomly distributed state the MET molecules form major/minor 
groove bound state. In the long time limit the minor groove bound state is found to be more 
favourable. The snaps are taken from a 50 ns long MD simulation using VMD.
62
  
 
We carry out a quantitative analysis in order to observe the groove selectivity of individual 
drug molecules. We assign a value of ‘0’ if it is bound to a minor groove and ‘1’ if it goes to the 
major groove. Any states other than these two are kept blank. The results are shown in 
Supplementary Figure S5. The molecules switch the grooves but spend a longer time (~10-30 
ns) in ‘0’ state that is the minor groove. Some molecules fluctuate between the two states 
(Figure S5 (e) and (g)) that indicates they are either at the two ends of the DNA or dangling 
from a backbone bond state.  
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In order to study interaction of MET with DNA we carry out several decisive experiments that 
are discussed in detail in the next section. The experimental studies aim to investigate the mode 
of interaction with DNA, that is, intercalating or outside groove binding drug. 
Experimental Results on DNA Binding.  
Preparation of DNA solution. We use commercially available Calf Thymus DNA (CT DNA) 
purchased from Sigma Aldrich Chemicals Pvt Ltd, India. Approximately 2mg of CT DNA is 
dissolved in 10 mM TrisHCl buffer in presence of 1mM EDTA. The EDTA is added to prevent 
in-situ denaturation of DNA strands. This stock solution is diluted further for spectroscopic 
studies. The UV-Vis absorption spectrum recorded for a 50 μg/mL dilution from this stock 
(Supporting Figure S3) shows a band at 260 nm characteristic of Nucleic Acids
63
.  An A260/A280 
ratio of 1.86 measured from this solution indicates absence of any protein impurities. 
 
Interaction of CT-DNA with Metformin – Electronic Absorption Spectra. The absorption 
band due to nucleic acid is known to undergo changes when partial unfolding of the double helix 
structure of DNA occurs as a result of molecular intercalation into DNA. This occurs because of 
exposure of the nucleobases, which is a consequence of structural distortion due to intercalation. 
Electronic absorption band of small molecules also undergo changes when bound to DNA. 
Hyperchromicity or hypochromicity of the absorption band can indicate the mode of interaction 
with DNA.
64
  
We record the electronic absorption spectrum of a 100 μM solution of Metformin and study the 
effect of addition of DNA to this solution. The electronic absorption spectrum of 100 μM in 
presence of increasing concentration of DNA (25 μg/mL to 200 μg/mL) is shown in Figure 17. 
We note that no change in the position of the absorption band of pure metformin, but a gradual 
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hyperchromicity is observed in the presence of DNA. This type of behaviour is documented in 
literature and suggests non – intercalative mode of interaction.18, 29, 65 
 
Figure 17. UV – visible absorption of Metformin (100 μM) in solution (black trace) and in 
the presence of increasing concentration of CT-DNA (25 μg/mL – red trace to 200 μg/mL – 
purple trace). The absorption band of pure metformin is highlighted in orange while that 
of pure CT DNA is highlighted in pink. The increase in the absorption (hyperchromism) of 
metformin in the presence of DNA (as shown in the arrow) suggests non – intercalation 
mode of interaction.    
 
Structural change of DNA on interaction with Metformin: Circular Dichroism study. 
Circular Dichroism spectroscopy is useful for studying changes in the structure of double – helix 
DNA strands on interaction with small molecules
66
. The circular dichroism spectrum of double 
helix DNA is characterized by a positive and negative  bands centred around 260 nm and a weak 
positive band around 220 nm.
67
 Changes in helicity because of intercalation results in alteration 
of the circular dichroism spectra of the DNA strands
68
. 
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We record the circular dichroism data in a JASCO J815 instrument.  A 1 mm path length 
quartz cuvette (Hellma) is used for the measurements. We measure the CD spectra of 100 μg/mL 
DNA in buffer as well as in the presence of increasing concentration of metformin (25 μg/mL to 
300 μg/mL) as shown in Figure 18. No particular change in the circular dichroism spectra is 
seen in the DNA samples incubated with metformin in the dichroism cantered around 260 nm. 
This rules out any significant structural distortion of the double helix which in turn excludes 
intercalation as a possible mode of DNA – metformin interaction.  Thus the circular dichroism 
data supports the indication obtained from the UV – vis absorption spectra that metformin does 
not intercalate into the DNA helix. However, we also notice an increasing distortion in the 
positive band at 220 nm. As metformin also absorbs ~230 nm, we speculate this to be the 
induced circular dichroism (ICD) of metformin in the presence of DNA. Small molecules like 
metformin, on binding to helical molecular moiety of DNA can exhibit ICD.
69-70
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Figure 18. Circular dichroism spectra of CT DNA (black trace) and DNA incubated with 
increasing stoichiometric ratios of Metformin (DNA:Met = 1:0.25 (red), 1:0.5 (blue), 1:1 
(orange), 1:2 (pink), 1:3 (green)). The characteristic negative and positive bands of the 
Cotton effect couplet centred on 275 nm do not undergo significant change in the presence 
of metformin as seen in the spectra. However the peak at 220 nm splits at a higher drug 
concentration. We speculate this as the induced circular dichroism (ICD) of metformin 
(natural UV absorption ~230 nm) by DNA. 
Photoluminescence studies on DNA – metformin interaction. Metformin in itself is a non – 
luminescent molecule that makes it unsuitable for photoluminescence studies. The data obtained 
from UV – visible and circular dichroism spectra indicate the presence of DNA – metformin 
interaction but rule out intercalation. This leads us to the conclusion that the possible mode of 
interaction may be groove binding. Acridine Orange and Hoechst are two standard fluorophores 
that shown enhancement in fluorescence on binding with DNA. While Hoechst is known to bind 
to DNA grooves, Acridine Orange intercalates within the DNA base pairs.    
We study the fluorescence of DNA in the presence of Acridine Orange and Hoechst 34580 
stain solution and note the changes in fluorescence when these are incubated with increasing 
concentrations of metformin. Fluorescence spectra are recorded in a 10 mm path length quartz 
cuvette (Hellma) on a Horiba Fluoromax fluorimeter. The Hoechst samples are excited at 390 
nm and emission is collected from 400 nm to 650 nm. A working concentration of 50 μg/mL 
0.02 μM Hoechst dye is used.  The Acridine Orange samples are excited at 460 nm and emission 
data is collected over 470 nm to 700 nm. A working concentration of 5 μM Acridine Orange is 
used for the experiments. DNA concentrations of both fluorescence experiments are 50 μg/mL.   
We see that for the DNA – Hoechst complex, there is a gradual decrease of fluorescence on 
incubation with metformin (Figure 19 (A)). As it is known that the Hoechst molecule shows 
intense fluorescence only when bound to the DNA, we infer from this observation that 
metformin in capable of partially replacing the bound Hoechst molecules in the minor grooves of 
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the DNA. However, we also note that the decrease in fluorescence in only seen in samples that 
have been incubated with metformin for over a week. This may indicate kinetic sluggishness of 
the competitive interaction between Metformin and Hoechst molecules for binding to the minor 
groove of DNA double helix.  
There is no significant change in fluorescence of the DNA – Acridine Orange complex upon 
incubation with metformin (Figure 19(B)), apart from a slight increase in intensity of 
fluorescence which may be due to increase in concentration of the DNA – AO bound complex 
with time. 
 
 
 
Figure 19. (A) Fluorescence spectra of Hoechst (black trace), DNA – Hoechst (red trace), 
DNA – Hoechst – Metformin (blue trace – 10 μM, pink trace – 20 μM). The characteristic 
emission peak of DNA bound Hoechst is marked in red dashed line, the emission of 
unbound Hoechst is marked in black dashed line. The shift in the fluorescence peak on 
Hoechst binding to DNA is indicated by the double - sided arrow. The decrease in 
fluorescence with increasing concentration of DNA is shown by the arrow pointing 
downwards. (B) Fluorescence spectra of DNA – Acridine Orange (red trace) and DNA – 
Acridine Orange – Metformin (blue trace – 10 μM, pink trace 20 μM). No decrease of 
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fluorescence in the presence of metformin establishes the inability of metformin in 
replacing the interacalating Acridine Orange molecules in the double stranded DNA helix.   
 SUMMARY AND CONCLUSIONS 
 
Here we have carried out experimental and theoretical investigations to explore and to 
understand characteristic properties of metformin hydrochloride. To the best of our knowledge, 
such studies have not been directed to MET earlier. This prototype study can well be followed in 
cases of other biologically relevant small molecules. We summarize our results with the help of 
the following points. 
i. We find several interesting characteristics of this important molecule not discussed in the 
literature. First, the protonated nitrogen rich molecule exhibits multiple protonated forms. 
It exhibits both a planar and non-planar form with the non-planar one being slightly more 
stable. The delocalised positive charge helps it to interact with charged surfaces of 
biomolecules.  
ii. We establish the abundance of the tautomer in a sample of metformin hydrochloride with 
the help of UV-Vis and IR spectroscopic studies. As adaptability could be a key feature 
of biological activity, this might hold the key to the diverse activity of MET. 
iii. We have generated a sustainable AMBER based force field for metformin for classical 
MD simulation. We have validated the force field and chosen the most abundant 
protonated form with respect to ab-initio calculations, diffusion and melting studies. The 
results from experiments and simulations are in good agreement. 
iv. The barrier of proton transfer between two mono protonated forms of metformin is 
calculated to be ~4-6 kcal/mol. This allows us to assume a possible co-existence of the 
two forms in aqueous solution and run the simulations accordingly. 
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v. We have observed solvation dynamics, hydrogen bond lifetime and rotational dynamics 
of different protonated forms of metformin. The solvation is ultrafast with an average 
time constant of 130-160 fs. The hydrogen bond lifetimes has direct consequence on the 
diffusion coefficient of different protonated forms. 
vi. Because of the reported cancer preventing and tumour supressing roles of metformin, its 
interaction with DNA draws avid attention. We perform several experimental and 
metadynamics simulation studies to understand the mode and pathway of binding. We 
observe that MET can bind to grooves and backbone of DNA within a few tens of ns MD 
timescale. The minor groove bound state is the most stable one. The extent of binding 
varies with the base pair ratios. We find that MET prefers AT rich domains over GC rich 
ones.  
vii. Our experiments also suggest a minor groove bound state as it can slowly replace a 
known strong minor groove binder Hoechst. This groove binding property can be 
exploited to encumber the normal DNA replication scheme that would finally result in a 
reduced cell multiplication. However, we do not observe any signature of intercalation. 
The CD spectra at higher drug concentrations show splitting and increase of the 220nm 
band that allows us to speculate the CD peak of the drug induced by DNA as the drug 
molecules gradually assemble to the grooves (Figure 16). 
One of our primary objectives has been to search for the characteristic features of small drug 
molecules (for example steroids, neurotransmitters, vitamins etc.) that allowed them to perform 
the function they are used for. Although one hopes to find certain universal chemical 
characteristics, we are aware that such a goal is difficult and would require the study of a large 
number of molecules. Many small molecules serve as powerful drugs because of their strong 
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effects on the human body. Often the microscopic aspects of such effects remain unclear. 
Metformin is not only a small molecule but characterized by unique features like five N atoms 
and in its hydrochloride form electron deficiency is delocalized over these five N atoms. In this 
particular case, the appearance of tautomeric forms on protonation seems to offer a clue – the 
molecule is adaptive to different environments. The protonation also makes it largely planar that 
might help it to slide through the cell membranes. With water molecules and ions all around, 
acquired polarity certainly could help, for example, in binding to DNA. Many of the above are 
not unexpected. But which of the above properties aids in its role as an anti-diabetic drug is 
unanswered. A quantitative study and molecular level understanding of the drug action and 
mechanism of metformin hydrochloride still remain elusive. 
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Supporting Information 
 
 
In the main text we report and discuss various aspects of structure, dynamics and DNA binding 
energetics of anti-diabetic drug metformin hydrochloride. Here, under supplementary figures, 
we provide the NMR and UV spectrum of metformin and UV spectrum of DNA which may be 
regarded as the test for purity. The initial configurations taken for metadynamics and residence 
time plots of metformin in DNA grooves are also provided. System size dependence of diffusion 
constant is discussed. We also provide the GAFF based and somewhat refined force field 
parameters of various mon-protonated forms of metformin in order to ensure the reproducibility 
of our MD and metadynamics simulations.  
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SUPPORTING FIGURES: 
 
 
Supporting Figure S1: 
1
H NMR spectrum of metformin crystals dissolved in D2O, showing the characteristic 
methyl protons at 3.03 δ ppm. The solvent peak is seen at 4.79 δ ppm. 
 
Supporting Figure S2: (Left) UV – visible absorption spectrum of Metformin showing characteristic 
absorption band centred around 230 nm (highlighted in orange). No noticeable shift of this band occurs in the 
concentration range shown (15 μM : black trace to 150 μm : purple trace, in increments of 15 μM every 
trace). (Right) Absorption – concentration plot of Metformin showing conformity with  
Lambert Beer approximation in the concentration range used with ε calculated to be  
10240 (±230) M
-1
cm
-1
.  
 42 
 
Supporting Figure S3: Electronic absorption spectrum of calf thymus DNA with the nucleic acid absorption 
band at 260 nm highlighted in light red. 
 
 
Supporting Figure S4: The initial structures of metadynamics simulation prepared using Schrodinger 
software package. The complex assumes a minor groove bound state with both (a) AT rich and (b) GC rich 
DNA. 
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Supporting Figure S5. Groove selectivity of metformin hydrochloride is represented in this figure. The state 
‘0’ represents a minor groove bound state and ‘1’ represents a major groove bound state. The blank regions 
are any state other that these two. It is clear that the drug molecule has long residence time when bound to a 
minor/major groove. Statistically the minor groove is more populated at a given time. MET can also switch 
grooves that is described by the jumps between ‘0’ and ‘1’ state.  
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SYSTEM SIZE DEPENDENCE OF DIFFUSION 
Table S1: We calculate diffusion constant (in cm
2
/s) for centre of mass diffusion of 
metformin molecules. In the main text, only the values for the largest system are provided. 
Here we provide the rest. 
 
System MET1 MET2 MET3 
500 water + 1MET 50.71( 0.11) 10   51.67( 0.60) 10   51.81( 0.54) 10   
1440 water + 3 MET 51.61( 0.24) 10   51.18( 0.09) 10   52.0( 0.3) 10   
2880 water + 6 MET 
51.90( 0.40) 10   50.89( 0.17) 10   51.07( 0.26) 10   
4320 water + 9 MET 51.13( 0.35) 10   51.25( 0.45) 10   51.47( 0.53) 10   
 
  
TOPOLOGY AND FORCE-FIELD OF METFORMIN HYDROCHLORIDE 
We have generated sustainable force fields for MD simulation of three different 
protonated forms of metformin hydrochloride using GAFF based atom type description and 
relevant quantum chemical calculations. Below we provide the force field details (partial 
charges, force constants etc.) and atomic coordinates of these three forms in order to ensure the 
reproducibility of our results and future uses/refinements. We prepare the files in GROMACS 
compatible format (that is .gro for coordinates and .itp for topology) so that these can be directly 
used. For the detailed meaning of each column of data represented below, please refer to any 
standard GROMACS manual
71
.  
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Coordinates of MET1 (.gro format) 
 
resid resname  atomtype  resnr        x               y                z 
 
    1MET1    N2    1  -0.284   0.107  -0.018 
    1MET1    H1    2  -0.257   0.203  -0.033 
    1MET1    H3    3  -0.382   0.086  -0.004 
    1MET1    C4    4  -0.191   0.011  -0.004 
    1MET1    N5    5  -0.223  -0.112   0.035 
    1MET1    H6    6  -0.147  -0.181   0.035 
    1MET1    H7    7  -0.318  -0.134   0.063 
    1MET1    N8    8  -0.062   0.043  -0.030 
    1MET1    H9    9  -0.046   0.133  -0.075 
    1MET1   C10   10   0.052  -0.040  -0.012 
    1MET1   N11   11   0.034  -0.168   0.002 
    1MET1   H12   12   0.122  -0.215   0.024 
    1MET1   N13   13   0.170   0.030  -0.021 
    1MET1   C14   14   0.187   0.158   0.050 
    1MET1   H15   15   0.092   0.214   0.054 
    1MET1   H16   16   0.221   0.140   0.154 
    1MET1   H17   17   0.261   0.218  -0.003 
    1MET1   C18   18   0.292  -0.052  -0.021 
    1MET1   H19   19   0.313  -0.095   0.079 
    1MET1   H20   20   0.284  -0.132  -0.096 
    1MET1   H21   21   0.376   0.014  -0.048 
 
Topology and Force-Field parameters of MET1 (.itp format) 
[ moleculetype ] 
; Name            nrexcl 
MET1          3 
 
[ atoms ] 
; nr       type   resnr  residue  atom   cgnr    charge     mass  
 
    1         nh      1    MET1    N2      1  -0.900266    14.0100   ; qtot -0.9003 
    2         hn      1    MET1    H1      2   0.461612     1.0080   ; qtot -0.4387 
    3         hn      1    MET1    H3      3   0.461612     1.0080   ; qtot 0.0230 
    4         cz      1    MET1    C4      4   0.925937    12.0100   ; qtot 0.9489 
    5         nh      1    MET1    N5      5  -0.900266    14.0100   ; qtot 0.0486 
    6         hn      1    MET1    H6      6   0.461612     1.0080   ; qtot 0.5102 
    7         hn      1    MET1    H7      7   0.461612     1.0080   ; qtot 0.9719 
    8         ne      1    MET1    N8      8  -0.666727    14.0100   ; qtot 0.3051 
    9         hn      1    MET1    H9      9   0.387913     1.0080   ; qtot 0.6930 
   10         c2      1    MET1   C10     10   0.716845    12.0100   ; qtot 1.4099 
   11         n2      1    MET1   N11     11  -0.859902    14.0100   ; qtot 0.5500 
   12         hn      1    MET1   H12     12   0.383606     1.0080   ; qtot 0.9336 
   13         nh      1    MET1   N13     13  -0.174984    14.0100   ; qtot 0.7586 
   14         c3      1    MET1   C14     14  -0.315343    12.0100   ; qtot 0.4433 
   15         h1      1    MET1   H15     15   0.145347     1.0080   ; qtot 0.5886 
   16         h1      1    MET1   H16     16   0.145347     1.0080   ; qtot 0.7340 
   17         h1      1    MET1   H17     17   0.145347     1.0080   ; qtot 0.8793 
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   18         c3      1    MET1   C18     18  -0.315343    12.0100   ; qtot 0.5640 
   19         h1      1    MET1   H19     19   0.145347     1.0080   ; qtot 0.7093 
   20         h1      1    MET1   H20     20   0.145347     1.0080   ; qtot 0.8547 
   21         h1      1    MET1   H21     21   0.145347     1.0080   ; qtot 1.0000 
 
[ bonds ] 
;    ai     aj   funct    c0      c1      
      1      2     1   0.10121 338569.28 
      1      3     1   0.10121 338569.28 
      1      4     1   0.13390 408358.40 
      4      5     1   0.13390 408358.40 
      4      8     1   0.12920 480406.88 
      5      6     1   0.10121 338569.28 
      5      7     1   0.10121 338569.28 
      8      9     1   0.10230 322670.08 
      8     10     1   0.12915 480406.88 
     10     11     1   0.12817 497142.88 
     10     13     1   0.13872 348276.16 
     11     12     1   0.10230 322670.08 
     13     14     1   0.14640 273298.88 
     13     18     1   0.14640 273298.88 
     14     15     1   0.10969 276646.08 
     14     16     1   0.10969 276646.08 
     14     17     1   0.10969 276646.08 
     18     19     1   0.10969 276646.08 
     18     20     1   0.10969 276646.08 
     18     21     1   0.10969 276646.08 
 
[ pairs ] 
;    ai     aj funct 
      1      6     1 
      1      7     1 
      1      9     1 
      1     10     1 
      2      5     1 
      2      8     1 
      3      5     1 
      3      8     1 
      4     11     1 
      4     13     1 
      5      9     1 
      5     10     1 
      6      8     1 
      7      8     1 
      8     12     1 
      8     14     1 
      8     18     1 
      9     11     1 
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      9     13     1 
     10     15     1 
     10     16     1 
     10     17     1 
     10     19     1 
     10     20     1 
     10     21     1 
     11     14     1 
     11     18     1 
     12     13     1 
     14     19     1 
     14     20     1 
     14     21     1 
     15     18     1 
     16     18     1 
     17     18     1 
 
[ angles ] 
;    ai     aj     ak   funct     c0         c1          
      1      4      5     1   120.14005 610.780320 
      1      4      8     1   123.46005 600.822400 
      2      1      3     1   115.12005 335.305760 
      2      1      4     1   121.15005 408.525760 
      3      1      4     1   121.15005 408.525760 
      4      5      6     1   121.15005 408.525760 
      4      5      7     1   121.15005 408.525760 
      4      8      9     1   110.80005 441.746720 
      4      8     10     1   118.18005 595.048480 
      5      4      8     1   123.46005 600.822400 
      6      5      7     1   115.12005 335.305760 
      8     10     11     1   113.82005 655.549120 
      8     10     13     1   123.46005 600.822400 
      9      8     10     1   110.80005 441.746720 
     10     11     12     1   110.80005 441.746720 
     10     13     14     1   123.71005 522.163200 
     10     13     18     1   123.71005 522.163200 
     11     10     13     1   124.27005 600.738720 
     13     14     15     1   109.79005 414.801760 
     13     14     16     1   109.79005 414.801760 
     13     14     17     1   109.79005 414.801760 
     13     18     19     1   109.79005 414.801760 
     13     18     20     1   109.79005 414.801760 
     13     18     21     1   109.79005 414.801760 
     14     13     18     1   114.51005 529.276000 
     15     14     16     1   108.46005 328.360320 
     15     14     17     1   108.46005 328.360320 
     16     14     17     1   108.46005 328.360320 
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     19     18     20     1   108.46005 328.360320 
     19     18     21     1   108.46005 328.360320 
     20     18     21     1   108.46005 328.360320 
 
[ dihedrals ] 
;    ai     aj     ak     al   funct  c0      c1     c2    
       
      1      4      5      6     1  180.00  17.3636  2 
      1      4      5      7     1  180.00  17.3636  2 
      1      4      8      9     1  180.00  17.3636  2 
      1      4      8     10     1  180.00  17.3636  2 
      2      1      4      5     1  180.00  17.3636  2 
      2      1      4      8     1  180.00  17.3636  2 
      3      1      4      5     1  180.00  17.3636  2 
      3      1      4      8     1  180.00  17.3636  2 
      4      8     10     11     1  180.00  17.3636  2 
      4      8     10     13     1  180.00  17.3636  2 
      5      4      8      9     1  180.00  17.3636  2 
      5      4      8     10     1  180.00  17.3636  2 
      6      5      4      8     1  180.00  17.3636  2 
      7      5      4      8     1  180.00  17.3636  2 
      8     10     11     12     1  180.00  17.3636  2 
      8     10     13     14     1  180.00  17.3636  2 
      8     10     13     18     1  180.00  17.3636  2 
      9      8     10     11     1  180.00  17.3636  2 
      9      8     10     13     1  180.00  17.3636  2 
     10     13     14     15     1  180.00  1.00000  6 
     10     13     18     19     1  180.00  1.00000  6 
     11     10     13     14     1  180.00  17.3636  2 
     11     10     13     18     1  180.00  17.3636  2 
     12     11     10     13     1  180.00  17.3636  2 
     14     13     18     19     1  180.00  1.00000  6 
     15     14     13     18     1  180.00  1.00000  6 
; improper dihedrals 
      4      5      1      8     4  0.00    4.60240  2 
     10     13      8     11     4  0.00    4.60240  2 
     13     10     14     18     4  0.00    4.60240  2 
      1      4      2      3     4  0.00    4.60240  2 
---------------------------------------------------------------------- 
 
Coordinates of MET2 (.gro format) 
 
resid resname  atomtype  resnr        x               y                z 
 
 
    1MET2    N2    1  -0.282   0.112  -0.005 
    1MET2    H1    2  -0.252   0.196   0.044 
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    1MET2    H3    3  -0.380   0.089   0.012 
    1MET2    C4    4  -0.196   0.004  -0.002 
    1MET2    N5    5  -0.226  -0.122  -0.000 
    1MET2    H6    6  -0.326  -0.136   0.012 
    1MET2    N7    7  -0.061   0.046  -0.011 
    1MET2    H8    8  -0.047   0.142  -0.039 
    1MET2    C9    9   0.050  -0.034  -0.001 
    1MET2   N15   10   0.035  -0.167   0.006 
    1MET2   H16   11   0.113  -0.226   0.032 
    1MET2   H17   12  -0.062  -0.200   0.006 
    1MET2   N10   13   0.170   0.025  -0.001 
    1MET2   C11   14   0.184   0.171   0.009 
    1MET2   H12   15   0.115   0.210   0.085 
    1MET2   H13   16   0.286   0.193   0.040 
    1MET2   H14   17   0.165   0.219  -0.088 
    1MET2   C18   18   0.291  -0.059  -0.007 
    1MET2   H19   19   0.313  -0.103   0.092 
    1MET2   H20   20   0.278  -0.138  -0.081 
    1MET2   H21   21   0.374   0.005  -0.037 
 
Topology and Force-Field parameters of MET2 (.itp format) 
 
[ moleculetype ] 
; Name            nrexcl 
MET2          3 
 
[ atoms ] 
;   nr       type  resnr residue  atom   cgnr    charge       mass  
 
    1         nh      1    MET2    N2      1  -0.876652    14.0100   ; qtot -0.8767 
    2         hn      1    MET2    H1      2   0.410536     1.0080   ; qtot -0.4661 
    3         hn      1    MET2    H3      3   0.410536     1.0080   ; qtot -0.0556 
    4         cz      1    MET2    C4      4   0.734160    12.0100   ; qtot 0.6786 
    5         n2      1    MET2    N5      5  -0.829116    14.0100   ; qtot -0.1505 
    6         hn      1    MET2    H6      6   0.389987     1.0080   ; qtot 0.2395 
    7         ne      1    MET2    N7      7  -0.493060    14.0100   ; qtot -0.2536 
    8         hn      1    MET2    H8      8   0.373652     1.0080   ; qtot 0.1200 
    9         c2      1    MET2    C9      9   0.509524    12.0100   ; qtot 0.6296 
   10         nh      1    MET2   N15     10  -0.699288    14.0100   ; qtot -0.0697 
   11         hn      1    MET2   H16     11   0.397876     1.0080   ; qtot 0.3282 
   12         hn      1    MET2   H17     12   0.397876     1.0080   ; qtot 0.7260 
   13         nh      1    MET2   N10     13  -0.024315    14.0100   ; qtot 0.7017 
   14         c3      1    MET2   C11     14  -0.314821    12.0100   ; qtot 0.3869 
   15         h1      1    MET2   H12     15   0.154654     1.0080   ; qtot 0.5415 
   16         h1      1    MET2   H13     16   0.154654     1.0080   ; qtot 0.6962 
   17         h1      1    MET2   H14     17   0.154654     1.0080   ; qtot 0.8509 
   18         c3      1    MET2   C18     18  -0.314821    12.0100   ; qtot 0.5360 
   19         h1      1    MET2   H19     19   0.154654     1.0080   ; qtot 0.6907 
   20         h1      1    MET2   H20     20   0.154654     1.0080   ; qtot 0.8453 
   21         h1      1    MET2   H21     21   0.154654     1.0080   ; qtot 1.0000 
 
[ bonds ] 
;    ai     aj funct         c0         c1         c2         c3 
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      1      2     1   0.10121 338569.280000 
      1      3     1   0.10121 338569.280000 
      1      4     1   0.13390 408358.400000 
      4      5     1   0.12820 497142.880000 
      4      7     1   0.12920 480406.880000 
      5      6     1   0.10230 322670.080000 
      7      8     1   0.10230 322670.080000 
      7      9     1   0.12915 480406.880000 
      9     10     1   0.13872 348276.160000 
      9     13     1   0.13872 348276.160000 
     10     11     1   0.10121 338569.280000 
     10     12     1   0.10121 338569.280000 
     13     14     1   0.14640 273298.880000 
     13     18     1   0.14640 273298.880000 
     14     15     1   0.10969 276646.080000 
     14     16     1   0.10969 276646.080000 
     14     17     1   0.10969 276646.080000 
     18     19     1   0.10969 276646.080000 
     18     20     1   0.10969 276646.080000 
     18     21     1   0.10969 276646.080000 
 
[ pairs ] 
;    ai     aj funct          
      1      6     1 
      1      8     1 
      1      9     1 
      2      5     1 
      2      7     1 
      3      5     1 
      3      7     1 
      4     10     1 
      4     13     1 
      5      8     1 
      5      9     1 
      6      7     1 
      7     11     1 
      7     12     1 
      7     14     1 
      7     18     1 
      8     10     1 
      8     13     1 
      9     15     1 
      9     16     1 
      9     17     1 
      9     19     1 
      9     20     1 
      9     21     1 
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     10     14     1 
     10     18     1 
     11     13     1 
     12     13     1 
     14     19     1 
     14     20     1 
     14     21     1 
     15     18     1 
     16     18     1 
     17     18     1 
 
[ angles ] 
;    ai     aj     ak   funct     c0       c1       
 
      1      4      5     2   124.27005 600.738720 
      1      4      7     2   123.46005 600.822400 
      2      1      3     2   115.12005 335.305760 
      2      1      4     2   121.15005 408.525760 
      3      1      4     2   121.15005 408.525760 
      4      5      6     2   110.80005 441.746720 
      4      7      8     2   110.80005 441.746720 
      4      7      9     2   118.18005 595.048480 
      5      4      7     2   113.82005 655.549120 
      7      9     10     2   123.46005 600.822400 
      7      9     13     2   123.46005 600.822400 
      8      7      9     2   110.80005 441.746720 
      9     10     11     2   115.09005 406.601120 
      9     10     12     2   115.09005 406.601120 
      9     13     14     2   123.71005 522.163200 
      9     13     18     2   123.71005 522.163200 
     10      9     13     2   112.82005 608.353600 
     11     10     12     2   115.12005 335.305760 
     13     14     15     2   109.79005 414.801760 
     13     14     16     2   109.79005 414.801760 
     13     14     17     2   109.79005 414.801760 
     13     18     19     2   109.79005 414.801760 
     13     18     20     2   109.79005 414.801760 
     13     18     21     2   109.79005 414.801760 
     14     13     18     2   114.51005 529.276000 
     15     14     16     2   108.46005 328.360320 
     15     14     17     2   108.46005 328.360320 
     16     14     17     2   108.46005 328.360320 
     19     18     20     2   108.46005 328.360320 
     19     18     21     2   108.46005 328.360320 
     20     18     21     2   108.46005 328.360320 
 
[ dihedrals ] 
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;    ai     aj     ak     al  funct   c0     c1      c2          
      1      4      5      6     1  180.0  17.36360  2 
      1      4      7      8     1  180.0  17.36360  2 
      1      4      7      9     1  180.0  17.36360  2 
      2      1      4      5     1  180.0  17.36360  2 
      2      1      4      7     1  180.0  17.36360  2 
      3      1      4      5     1  180.0  17.36360  2 
      3      1      4      7     1  180.0  17.36360  2 
      4      7      9     10     1  180.0  17.36360  2 
      4      7      9     13     1  180.0  17.36360  2 
      5      4      7      8     1  180.0  17.36360  2 
      5      4      7      9     1  180.0  17.36360  2 
      6      5      4      7     1  180.0  17.36360  2 
      7      9     10     11     1  180.0  17.36360  2 
      7      9     10     12     1  180.0  17.36360  2 
      7      9     13     14     1  180.0  17.36360  2 
      7      9     13     18     1  180.0  17.36360  2 
      8      7      9     10     1  180.0  17.36360  2 
      8      7      9     13     1  180.0  17.36360  2 
      9     13     14     15     1  180.0   1.00000  6 
      9     13     18     19     1  180.0   1.00000  6 
     10      9     13     14     1  180.0  17.36360  2 
     11     10      9     13     1  180.0  17.36360  2 
     12     10      9     13     1  180.0  17.36360  2 
;improper dihedral 
      1      4      2      3     2  0.00    4.60240  2 
      4      1      7      5     2  0.00    4.60240  2 
      9     10      7     13     2  0.00    4.60240  2 
     13      9     14     18     2  0.00    4.60240  2 
---------------------------------------------------------------------- 
 
Coordinates of MET3 (.gro format) 
 
resid resname  atomtype  resnr        x               y                z 
    
    1MET3     N2    1   2.926   2.715   2.572 
    1MET3     H1    2   2.901   2.794   2.516 
    1MET3     H3    3   3.024   2.702   2.596 
    1MET3     C4    4   2.828   2.635   2.619 
    1MET3     N5    5   2.864   2.526   2.691 
    1MET3     H6    6   2.960   2.514   2.721 
    1MET3     H7    7   2.794   2.477   2.744 
    1MET3     N8    8   2.704   2.671   2.591 
    1MET3     C9    9   2.596   2.592   2.597 
    1MET3    N15   10   2.604   2.457   2.578 
    1MET3    H16   11   2.520   2.402   2.565 
    1MET3    H17   12   2.686   2.420   2.533 
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    1MET3    N10   13   2.476   2.647   2.619 
    1MET3    C18   14   2.353   2.566   2.613 
    1MET3    H19   15   2.351   2.490   2.692 
    1MET3    H20   16   2.268   2.633   2.629 
    1MET3    H21   17   2.341   2.519   2.515 
    1MET3    C11   18   2.460   2.789   2.652 
    1MET3    H12   19   2.557   2.838   2.648 
    1MET3    H13   20   2.394   2.836   2.579 
    1MET3    H14   21   2.418   2.799   2.752 
 
 
Topology and Force-Field parameters of MET3 (.itp format)  
 
[ moleculetype ] 
; Name            nrexcl 
MET3         3 
 
[ atoms ] 
;   nr       type  resnr residue  atom   cgnr    charge      mass 
 
    1         na      1    MET3     N2      1  -0.876975    14.0100   ; qtot -0.8770 
    2         hn      1    MET3     H1      2   0.430501     1.0080   ; qtot -0.4465 
    3         hn      1    MET3     H3      3   0.430501     1.0080   ; qtot -0.0160 
    4         cz      1    MET3     C4      4   0.838081    12.0100   ; qtot 0.8221 
    5         na      1    MET3     N5      5  -0.876975    14.0100   ; qtot -0.0549 
    6         hn      1    MET3     H6      6   0.430501     1.0080   ; qtot 0.3756 
    7         hn      1    MET3     H7      7   0.430501     1.0080   ; qtot 0.8061 
    8         ne      1    MET3     N8      8  -0.615647    14.0100   ; qtot 0.1905 
    9         cz      1    MET3     C9      9   0.613622    12.0100   ; qtot 0.8041 
   10         na      1    MET3    N15     10  -0.961600    14.0100   ; qtot -0.1575 
   11         hn      1    MET3    H16     11   0.447151     1.0080   ; qtot 0.2897 
   12         hn      1    MET3    H17     12   0.447151     1.0080   ; qtot 0.7368 
   13         na      1    MET3    N10     13   0.009854    14.0100   ; qtot 0.7467 
   14         c3      1    MET3    C18     14  -0.345405    12.0100   ; qtot 0.4013 
   15         h1      1    MET3    H19     15   0.157357     1.0080   ; qtot 0.5586 
   16         h1      1    MET3    H20     16   0.157357     1.0080   ; qtot 0.7160 
   17         h1      1    MET3    H21     17   0.157357     1.0080   ; qtot 0.8733 
   18         c3      1    MET3    C11     18  -0.345405    12.0100   ; qtot 0.5279 
   19         h1      1    MET3    H12     19   0.157357     1.0080   ; qtot 0.6853 
   20         h1      1    MET3    H13     20   0.157357     1.0080   ; qtot 0.8426 
   21         h1      1    MET3    H14     21   0.157357     1.0080   ; qtot 1.0000 
 
[ bonds ] 
;    ai     aj funct         c0         c1       
      1      2     1   0.10100 341749.120000 
      1      3     1   0.10100 341749.120000 
      1      4     1   0.14010 332544.320000 
      4      5     1   0.14010 332544.320000 
      4      8     1   0.12920 480406.880000 
      5      6     1   0.10100 341749.120000 
      5      7     1   0.10100 341749.120000 
      8      9     1   0.12920 480406.880000 
      9     10     1   0.14010 332544.320000 
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      9     13     1   0.14010 332544.320000 
     10     11     1   0.10100 341749.120000 
     10     12     1   0.10100 341749.120000 
     13     14     1   0.14629 274219.360000 
     13     18     1   0.14629 274219.360000 
     14     15     1   0.10969 276646.080000 
     14     16     1   0.10969 276646.080000 
     14     17     1   0.10969 276646.080000 
     18     19     1   0.10969 276646.080000 
     18     20     1   0.10969 276646.080000 
     18     21     1   0.10969 276646.080000 
 
[ pairs ] 
;    ai     aj funct         
      1      6     1 
      1      7     1 
      1      9     1 
      2      5     1 
      2      8     1 
      3      5     1 
      3      8     1 
      4     10     1 
      4     13     1 
      5      9     1 
      6      8     1 
      7      8     1 
      8     11     1 
      8     12     1 
      8     14     1 
      8     18     1 
      9     15     1 
      9     16     1 
      9     17     1 
      9     19     1 
      9     20     1 
      9     21     1 
     10     14     1 
     10     18     1 
     11     13     1 
     12     13     1 
     14     19     1 
     14     20     1 
     14     21     1 
     15     18     1 
     16     18     1 
     17     18     1 
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[ angles ] 
;    ai     aj     ak  funct       c0       c1        
 
      1      4      5     1   109.33005 611.700800 
      1      4      8     1   116.14505 633.892736 
      2      1      3     1   116.80005 333.632160 
      2      1      4     1   119.28005 395.806400 
      3      1      4     1   119.28005 395.806400 
      4      5      6     1   119.28005 395.806400 
      4      5      7     1   119.28005 395.806400 
      4      8      9     1   118.18005 595.048480 
      5      4      8     1   116.14505 633.892736 
      6      5      7     1   116.80005 333.632160 
      8      9     10     1   116.14505 633.892736 
      8      9     13     1   116.14505 633.892736 
      9     10     11     1   119.28005 395.806400 
      9     10     12     1   119.28005 395.806400 
      9     13     14     1   117.20005 534.296800 
      9     13     18     1   117.20005 534.296800 
     10      9     13     1   109.33005 611.700800 
     11     10     12     1   116.80005 333.632160 
     13     14     15     1   108.78005 416.977440 
     13     14     16     1   108.78005 416.977440 
     13     14     17     1   108.78005 416.977440 
     13     18     19     1   108.78005 416.977440 
     13     18     20     1   108.78005 416.977440 
     13     18     21     1   108.78005 416.977440 
     14     13     18     1   125.59005 505.761920 
     15     14     16     1   108.46005 328.360320 
     15     14     17     1   108.46005 328.360320 
     16     14     17     1   108.46005 328.360320 
     19     18     20     1   108.46005 328.360320 
     19     18     21     1   108.46005 328.360320 
     20     18     21     1   108.46005 328.360320 
 
[ dihedrals ] 
;    ai     aj     ak     al   funct   c0         c1    c2    
       
      1      4      5      6     1  180.0000  17.36360  2 
      1      4      5      7     1  180.0000  17.36360  2 
      1      4      8      9     1  160.0000  17.36360  2 
      2      1      4      5     1  180.0000  17.36360  2 
      2      1      4      8     1  180.0000  17.36360  2 
      3      1      4      5     1  180.0000  17.36360  2 
      3      1      4      8     1  180.0000  17.36360  2 
      4      8      9     10     1  150.0000  17.36360  2 
      4      8      9     13     1  160.0000  17.36360  2 
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      5      4      8      9     1  160.0000  17.36360  2 
      6      5      4      8     1  180.0000  17.36360  2 
      7      5      4      8     1  180.0000  17.36360  2 
      8      9     10     11     1  180.0000  17.36360  2 
      8      9     10     12     1  180.0000  17.36360  2 
      8      9     13     14     1  180.0000  17.36360  2 
      8      9     13     18     1  180.0000  17.36360  2 
      9     13     14     15     1   0.000000  1.00000  2 
      9     13     18     19     1   0.000000  1.00000  2 
     10      9     13     14     1  180.0000  17.36360  2 
     10      9     13     18     1  180.0000  17.36360  2 
     11     10      9     13     1  180.0000  17.36360  2 
     12     10      9     13     1  180.0000  17.36360  2 
     14     13     18     19     1   0.00000  1.00000   2 
     15     14     13     18     1   0.00000  1.00000   2 
; improper dihedrals 
      3      1      4      2     4  180.0000  4.60240   2 
      1      5      4      8     4  180.0000  4.60240   2 
      4      6      5      7     4  180.0000  4.60240   2 
     10     13      9      8     4  180.0000  4.60240   2 
      9     11     10     12     4  180.0000  4.60240   2 
----------------------------------------------------------------------------------------------------------------------------- ------------- 
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